Discovery of auto-antibodies in Long-COVID

Discovery of auto-antibodies in Long-COVID - Discovery of auto-antibodies in Long-COVID

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53317

Enrollment

Registered

2023-04-05

Start date

2023-04-01

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-infectioeuze ziekten long-covid PASC

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: * Non-hospitalized individuals with prior confirmed diagnosis of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection by reverse transcription-polymerase chain reaction testing or serology (wantai) testing * No Long-Covid symptoms present before confirmed diagnosis of SARS-CoV-2 * Individuals with diagnosed PASC by an Amsterdam UMC post-covid physician * Aged between 18-65 years

Exclusion criteria

Exclusion criteria: * Pregnancy * Chronic illness (including orthopaedic, endocrinological, haematological, malignant, gastrointestinal, neurological, muscle or inflammatory disorders) likely to significantly impact on exercise performance

Design outcomes

Primary

Measure	Time frame
Outcome parameters for autoantibody analysis by HuProt will be the presence of autoantibodies that are unique for the long-COVID patients in venous blood	—

Secondary

Measure	Time frame
The binding of the recombinant antibodies to the antigens that we identified by HuProt analysis	—

Countries

Netherlands

Outcome results